Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

“In its letter, the FDA noted that so far, it has reviewed safety in only 131 randomized patients treated with ZYESAMI.”

https://www.prnewswire.com/news-releases/us-food-and-drug-administration-declines-emergency-use-authorization-for-zyesami-aviptadil-for-patients-with-critical-covid-19-with-respiratory-failure-301417228.html?fbclid=IwAR3_cYj8GViBA0asnnbjHH0kFfyXoeb4EyGaOZWqHmTWDmrpS8AWw3Y5Rg8

Note the use of the word “only”.

In IPIX’ study, only around 60 patients with COVID-19 will have received brilacidin.